1. Powered by Bioscience, Focused on Products1 Pharming Overview May 2006 This presentation contains forward looking statements that involve known and unknown risks, uncertainties and other factors, which may cause the actual results, performance or achievements of the Company to be materially different from the results, performance or achievements expressed or implied by these forward looking statements. Powered by Bioscience, Focused on Products

2. 2 Overview History Based in Leiden, Netherlands and USA Euronext listing; 1989 - 2001 ‘Research Era’ Production of recombinant proteins for restoration and repair Role of protein cascades (Complement, Clotting) 2002 - 2005 ‘Turnaround & Refocus’ 240 40 60 employees Lead product rhC1INH being filed for HAE Clinical work on major new indications rhLactoferrin filed for GRAS indication in USA rhFibrinogen and rhCollagen development Novel protein manufacturing system validated Technology Organisation Products

3. Powered by Bioscience, Focused on Products3 Survival Focus Innovation Collaboration Financing Research Organisation rhC1 INH rh LF Cash Flow Restructuring Compassionate Use Manufacturing Marketing Diosynth Paul Capital Novathera DNage Strategic Evolution 2001A2002A2004A2005A2006 - 07 Equity€ (1) M € 11 M€ 36 M€ 29 M€ 50 M + Debt € (24) M€ (5) MNear Zero Near ZeroNear Zero Annual Loss€ (54) M€ (1) M € (14) M € (18) MZCB Employees25040 48 6060+ Products11 4 4+6+ Mkt Cap€ 4 M€ 16 M€ 150 M€ 325 M

4. Powered by Bioscience, Focused on Products4 Product Pipeline > € 500 million > € 1 billion € 100 million > € 1 billion rhC1INH rhFibrinogen rhFib Sealant rhLactoferrin rhCollagen Novathera Combos Technology ProductApplicationMarket Size Status HAE New Indications Intermediate Control bleeding Nutraceutical Anti-infective Intermediate Cosmetic / Other Tissue Repair Catheters, Stents Protein Production Phase III Filing in first market In the clinic Intermediate Device Food (GRAS) Device Intermediate Device Under Development Licensing Accelerate Product Flow to the Market

5. Powered by Bioscience, Focused on Products5 Protein Production Technology Generate genetic constructs Develop founder/ mini-herd Expand herd Select protein Purify protein from milk Formulate Protein therapeutic

6. Powered by Bioscience, Focused on Products6 HAE - Patient Centric Approach Patient Register facilitating patient care relationships with key opinion leaders share information with regulatory authorities relationship with patient organizations A congenital deficiency of functional C1 inhibitor (C1INH) characterised by recurrent localised angioedema due to uncontrolled activation of complement and contact systems 22,000 patients, 160,000 attacks per year

7. Powered by Bioscience, Focused on Products7 Rec. Human C1 inhibitor Phase III for HAE Rapid relief (usually 15 minutes) Complete resolution (12 - 24 hours) No ADRs reported Report published April 2005

8. Powered by Bioscience, Focused on Products8 Rec. Human Lactoferrin Filed with US FDA for GRAS For functional and sport foods Doses of upto 2g/kg in toxicity studies Safe for oral use Report published Jan 2006

9. Powered by Bioscience, Focused on Products9 Future Outlook 2006 – 08 Capitalize on solid financial position Strong news flow from filings, partnerships and launches for rhC1INH and rhLF Partnerships for Pharming technology platforms and product pipeline Generate sustainable revenues via rhC1INH and rhLF launches Establish critical mass to build a biotechnology company with world class R&D and commercial capabilities